By Stephen Nakrosis
Protalix BioTherapeutics' Chief Financial Officer Eyal Rubin plans to leave the company and has given his six months notice.
Rubin is leaving to pursue other opportunities, Protalix said Wednesday.
The biopharmaceutical said Rubin has been CFO since 2019, and before that worked at BrainStorm Cell Therapeutics and Teva Pharmaceutical Industries.
During the six month period, Rubin will continue to serve in his current role and provide transition services to Protalix.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 23, 2025 18:14 ET (22:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.